Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 29 of 102, showing 5 Applications out of 508 total, starting on record 141, ending on 145

# Protocol No Study Title Investigator(s) & Site(s)

141.

ECCT/24/01/03   Doxy Short Course
    A Phase 4 Study of a 3-Day Vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection.   
Principal Investigator(s)
1. Jackson Nyangaresi Nyandoro
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Pwani Research Centre (Mombasa county)
2. KEMRI CCR-PHRD (Nairobi City county)
 
View

142.

ECCT/12/11/02   Not provided
    A5297: An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of   Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and <350 cells/mm3   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

143.

ECCT/24/06/06   EDE Scanner Study
    A non-interventional clinical validation study of the Exponential Deep Examination (EDE) scanner in the detection of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria.   
Principal Investigator(s)
1. Bernhards Ogutu
2. Lucas Tina
3. VIDELIS NDUBA
Site(s) in Kenya
1. VICTORIA BIOMEDICAL RESEARCH INSTITUTE (Kisumu county)
2. KEMRI/CRDR Siaya Clinical Trials Annex (Siaya county)
3. Ahero Clinical Trials Unit (Kisumu county)
 
View

144.

ECCT/25/02/03   NOZE20240219TB
    “Validation of a Digital Olfaction Based Breathalyzer Device for Non-Invasive Detection of Volatile Biomarkers in Patients with and without Tuberculosis: Case Control Study”.   
Principal Investigator(s)
1. Ibrahim Daud
Site(s) in Kenya
KEMRI/WRP CRC Kericho
 
View

145.

ECCT/21/09/04   Recombinant COVID-19 Vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older            
Principal Investigator(s)
1. Sylvester Kimaiyo
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. Moi Teaching and Referral Hospital (Uasin Gishu county)
3. Kenya Medical Research Institute, Kilifi (Kilifi county)
 
View